SCHEDULE: Nantahala Capital Management Boosts Stake in ADC Therapeutics

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.69% of ADC Therapeutics SA's common shares as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively hold a significant stake in ADC Therapeutics SA.
• As of June 30, 2026, the Reporting Persons beneficially own 12,326,184 shares of common stock.
• This ownership represents 9.69% of the total outstanding shares of ADC Therapeutics SA.
• The filing indicates shared voting and dispositive power over these shares.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant beneficial ownership by Nantahala Capital Management, LLC and its principals, suggesting confidence in ADC Therapeutics SA.

Positives

• Significant beneficial ownership of 9.69% by Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, indicates strong investor conviction.
• The reporting persons are investment advisers, suggesting a strategic investment rather than a passive one.
• The filing confirms that the shares are held in the ordinary course of business, implying a long-term investment perspective.

Negatives

• The filing does not disclose any negative financial performance or operational issues.
• No specific details are provided regarding the exact strategy behind the increased ownership.

Risks

• As with any significant equity holding, the value of the investment is subject to market fluctuations and the performance of ADC Therapeutics SA.
• Potential for future changes in ownership levels by Nantahala Capital Management, LLC, which could impact share price.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from the company. The outlook is based on the reporting persons' investment strategy.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake building by investment firms like Nantahala Capital Management often signals a belief in the target company's growth prospects or undervaluation within its sector, in this case, biotechnology.

Comparison to Industry Standards

• Holding a 9.69% stake is a substantial position, often considered significant by institutional investor standards, indicating a high level of commitment.
• For an investment adviser, this percentage typically represents a core holding within a managed portfolio, suggesting a belief in the company's long-term value proposition compared to other investment opportunities.

Stakeholder Impact

• Shareholders may view the increased stake as a positive signal of confidence in the company's future, potentially supporting share price.
• Management of ADC Therapeutics SA may see this as validation of their strategy, but also increased scrutiny from a significant shareholder.

Next Steps

• Continued monitoring of ADC Therapeutics SA's performance and strategic developments by Nantahala Capital Management, LLC.
• Potential for further adjustments to the ownership stake based on market conditions and company performance.

Key Dates

Recommendation

The filing indicates a significant investment by Nantahala Capital Management, LLC, suggesting confidence. However, without company-specific financial results or forward-looking guidance in this particular filing, a 'hold' recommendation is prudent, pending further information on ADC Therapeutics SA's performance and strategy.

Keywords

ADC Therapeutics SA, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial Ownership, Common Shares, Investment Adviser